Latest Breaking News On - Dash dhanak - Page 1 : comparemela.com

Deciphera Pharmaceuticals, Inc (NASDAQ:DCPH) Q2 2023 Earnings Call Transcript

Operator: Good morning, everyone. And welcome to the Deciphera Pharmaceuticals Second Quarter 2023 Financial Results Conference Call. Today’s call is being recorded.

United kingdomPeter lawsonTucker kellyReni benjaminBrad caninoJen larsonMatt shermanChris raymondDan martinMichael schmidtDan flynnEun yangTyler van burenSteve hoerterPiper sandlerMargarida duarte

Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results

– Second Quarter 2023 Total Revenue of $38.3 Million; Net Product Revenue for QINLOCK® (ripretinib) Increased 18% to $37.3 Million Compared to Second Quarter 2022 –– Top-line Results for MOTION Pivotal Phase 3 Study of Vimseltinib Expected in Fourth Quarter 2023 –– INSIGHT Pivotal Phase 3 Study of QINLOCK in Second-.

New zealandUnited statesUnited kingdomHong kongDaniell flynnDan flynnJamesa bristolMaghan meyersSteve hoerterDashyant dhanakDavid rosenPfizer incDeciphera pharmaceuticals incResearch engineExchange commissionDeciphera pharmaceuticals

Deciphera Pharmaceuticals Announces Retirement of Daniel L Flynn, Ph D , and Appointment of Dashyan

Deciphera Pharmaceuticals Announces Retirement of Daniel L Flynn, Ph D , and Appointment of Dashyan
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

United kingdomNew zealandUnited statesHong kongMaghan meyersJim bristolSteve hoerterJamesa bristolDashyant dhanakDaniell flynnDavid rosenChairperson or coCompany founderPfizer incDeciphera pharmaceuticalsUniversity of london

Deciphera Pharmaceuticals Announces Retirement of Daniel L Flynn, Ph D , and Appointment of Dashyant Dhanak, Ph D , as Executive Vice President and Chief Scientific Officer

03.08.2023 - Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that the Company’s Founder, . Seite 1

Steve hoerterDeciphera pharmaceuticalsChief executive officerDash dhanakChief scientific

Incyte s Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session Seite 1

11.12.2022 - Incyte (Nasdaq:INCY) today announced new research detailing the development and mechanism of action of INCA033989, an Incyte-discovered, investigational novel anti-mutant calreticulin (CALR)-targeted monoclonal antibody. Pre-clinical data indicate . Seite 1

United statesSrdan verstovsekAmerican society of hematologyUniversity of texas md anderson cancer centerDepartment of leukemiaPlenary scientific sessionHematology disease topicsAmerican societyAnnual meetingNew orleansDash dhanakExecutive vice presidentChief scientific officer